Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.25%
1,104.10
+2.73
+0.25%
—1,101.371,103.631,105.311,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.50%
604.16
-9.19
-1.50%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.09%
1,197.81
-1.02
-0.09%
—1,198.831,199.681,199.751,182.41——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,740.41
-15.54
-0.88%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.44
-4.07
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.31%
840.90
-2.62
-0.31%
—843.52843.35846.40837.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.38%
215.13
-0.82
-0.38%
—215.95215.95216.84215.06——
SIXT
Technology
SIXT
Technology
SIXT
+2.86%
3,228.71
+89.80
+2.86%
—3,138.913,189.303,230.853,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
935.87
+1.50
+0.16%
—934.37934.72938.26927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.37%
1,457.12
-20.31
-1.37%
—1,477.431,474.121,474.121,451.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.83%
2,399.84
+19.65
+0.83%
—2,380.192,389.342,403.042,380.47——
4502:TYO
Takeda Pharmaceutical Co Ltd
Â¥5,335.00
+0.08%
(+4.00) 1D
Apr 24, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4502...
Open
Â¥5,352
High
Â¥5,378
Low
Â¥5,306
Mkt. cap
8.49T
Avg. vol.
4.44M
Volume
2.39M
Dividend
3.71%
Quarterly dividend
Â¥49
Ex dividend date
Sep 29, 2025
P/E ratio
73.83
52-wk high
Â¥6,033
52-wk low
Â¥4,000
EPS
Â¥72
Shares outstanding
784.48M
No. of employees
47K
News stories
From sources across the web
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOChristophe Weber | Christophe Weber
Employees47.5K
FoundedJun 12, 1781
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Last report
Jan 29, 2026
Fiscal Period
Q3 2026
Normalized EPS / Estimate
-/ -JPY
Revenue / Estimate
1.19T/ (1.20T est.)JPY
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.05T
1.11T
1.11T
1.19T
Cost of goods sold
373.28B
384.68B
380.06B
401.15B
Cost of revenue
373.28B
384.68B
380.06B
401.15B
Research and development expenses
216.01B
143.89B
161.48B
175.23B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
295.83B
255.88B
253.55B
282.78B
Operating expense
557.10B
535.14B
562.57B
661.30B
Total operating expenses
930.38B
919.82B
942.63B
1.06T
Operating income
123.02B
186.86B
170.17B
129.25B
Other non operating income
-24.86B
-77.96B
77.96B
-294.52B
EBT including unusual items
-107.30B
150.63B
28.17B
133.86B
EBT excluding unusual items
100.18B
152.93B
128.86B
114.17B
Income tax expense
-4.20B
26.35B
39.90B
30.13B
Effective tax rate
3.92%
17.49%
141.64%
22.51%
Other operating expenses
-91.26B
6.03B
16.12B
67.13B
Net income
-103.16B
124.24B
-11.80B
103.64B
Net profit margin
-9.79%
11.23%
-1.06%
8.70%
Earnings per share
-
-
-
-
Interest and investment income
9.85B
73.76B
43.92B
278.65B
Interest expense
-7.82B
-29.20B
-161.10B
-
Net interest expenses
2.03B
44.56B
-117.18B
278.65B
Depreciation and amortization charges
-
-
-
-
EBITDA
221.72B
368.50B
355.15B
182.70B
Gain or loss from assets sale
-2.39B
-17.32B
303.00M
358.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer